Vaccitech plc (VACC) Share Price Today, Stock Analysis, Annual Report | Value Research Vaccitech plc (VACC) - Get live share price today, stock analysis, price valuation, performance, fundamentals, market cap, share holding, financial report of US stocks.
  • Price Change
  • Market Capitalisation market-capitalisation-info $87 Mln

  • 12 Month Earnings monthly-earning $24 Mln
  • Price to Earnings price-to-earning --

Vaccitech plc (VACC) Share Price

$1.68

As on 22-Sep-2023 16:00 EDT

up-down-arrow $-0.01-0.59%

  • Prev Close info

    $1.69

  • Day's Openinfo

    $1.64

  • Today's Highinfo

    $1.75

  • Today's Lowinfo

    $1.64

  • Today's Volumeinfo

    4,454

Please wait...

Vaccitech plc (VACC) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Vaccitech (VACC)
-28.51 -15.58 -26.32 -50.00 -- -- --
S&P BSE Sensex
8.49 1.22 3.91 11.02 20.17 12.37 12.54
S&P Small-Cap 600#
-0.96 -4.96 -1.70 6.06 11.70 1.31 6.60
As on 22-Sep-2023  |  #As on 24-Sep-2023
2022
Vaccitech (VACC)
-78.85
S&P Small-Cap 600
-17.42
S&P BSE Sensex
4.44

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Vaccitech plc (VACC) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Vaccitech plc (VACC)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        CEO & Director

        Mr. William J. Enright MBA

        Chief Medical Officer

        Dr. Margaret Marshall M.D.

        Headquarters

        Oxford

        FAQs for Vaccitech plc (VACC)

        The total asset value of Vaccitech plc (VACC) stood at $ 274 Mln as on 31-Mar-23

        The share price of Vaccitech plc (VACC) is $1.680000 (NASDAQ) as of 22-Sep-2023 16:00 EDT. Vaccitech plc (VACC) has given a return of -50% in the last 1 years.

        Vaccitech plc (VACC) has a market capitalisation of $ 87 Mln as on 23-Jun-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Vaccitech plc (VACC) is 0.36 times as on 23-Jun-2023, a -0.86% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Vaccitech plc (VACC) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Vaccitech plc (VACC) and enter the required number of quantities and click on buy to purchase the shares of Vaccitech plc (VACC).

        Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. V

        The CEO & director of Mr. William J. Enright MBA. is Vaccitech plc (VACC), and CFO & Sr. VP is Dr. Margaret Marshall M.D..

        The promoters of Vaccitech plc (VACC) have pledged 0% of the total equity as on Mar-23.

        Vaccitech plc (VACC) Ratios
        Return on equity(%)
        -6.48
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        Yes, TTM profit after tax of Vaccitech plc (VACC) was $24 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $87.48 Mln
        • Revenue (TTM)revenue-information $30.15 Mln
        • Earnings (TTM) earning-information $23.94 Mln
        • Cash date-information $191.33 Mln
        • Total Debt info $10.65 Mln
        • Insider's Holding 26.38%
        • Liquidity liquidity High
        • 52 Week range week-range $1.64 - 3.36
        • Shares outstanding share-outstanding 38,369,800

        About The Company

        • IPO Date 30-Apr-2021
        • CEO & Director Mr. William J. Enright MBA
        • Chief Medical Officer Dr. Margaret Marshall M.D.
        • Listing key-listing NASDAQ: VACC
        • Country United Kingdom
        • Headquarters headquarters Oxford
        • Website website https://www.vaccitech.co.uk
        • Business

          Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic...  programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. V  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon